Alumis stock jumps 129% after Phase 3 psoriasis data; ALMS hits new 52-week high
Alumis shares surged 129% Tuesday after its psoriasis pill, envudeucitinib, met all main goals in Phase 3 trials. About 65% of patients reached PASI 90 and over 40% achieved complete clearance at week 24. The company reported no new safety concerns and plans to file for FDA approval in the second half of 2026. Traders are watching durability and safety data.